, Sept. 18 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO - news) today announced that it has signed a collaborative research agreement with Merck & Co., Inc. (NYSE: MRK - news). Under the terms of the agreement, Sangamo will provide its Universal GeneTools(TM) to Merck for its internal use...
``Merck's decision to use Sangamo's proprietary technology in their internal programs reflects the growing belief that our technology provides a novel way to identify and control gene expression,'' said Edward Lanphier, president and chief executive officer of Sangamo. ``With a more detailed understanding of the disease process, we hope to accelerate the discovery and development of important therapeutics.''
Leading pharmaceutical and biotechnology companies utilizing ZFPs include: AstraZeneca, Bayer Corporation, Bristol-Myers Squibb, DuPont Pharmaceuticals, Genset SA, Glaxo Wellcome, Hoffmann-LaRoche, Immunex, The R.W. Johnson Pharmaceutical Research Institute (PRI), Japan Tobacco, Merck & Co., Inc., Merck KGaA, Millennium Pharmaceuticals, Pfizer, Pharmacia & Upjohn, Procter & Gamble Pharmaceuticals, Schering AG, SmithKline Beecham, Warner-Lambert, and Zaiya. In addition, Sangamo has a strategic alliance with Edwards Lifesciences Corporation to develop novel therapeutics for the treatment of cardiovascular disease. |
